U.S. Markets close in 4 hrs 2 mins

KeyBanc Out Bullish On Olin, Says Chemical Manufacturer Has 'Favorable Supply-Demand Dynamics'

Priya Nigam

Olin Corporation (NYSE: OLN) has strong positioning as a global chlorine derivatives leader and its Dow assets have been integrated well, according to KeyBanc Capital Markets, which is projecting year-on-year earnings growth for the company in 2019.

The Analyst

KeyBanc’s Michael Sison initiated coverage of Olin with an Overweight rating and $30 price target.  

The Thesis

Olin is estimated to have generated EBITDA growth of more than 30 percent to $1.23 billion in 2018, Sison said in the Sunday note. 

The strong performance was driven mainly by a supportive pricing environment in caustic soda, chlorine, ethylene dichloride and other chlorine derivatives, the analyst said. The company should be able to maintain this performance “over the next few years” owing to “favorable supply-demand dynamics,” he said. 

Olin is likely to generate EBITDA growth in 2019 — albeit at a low-single-digit pace — against a slowing economic backdrop, Sison said.

Headwinds are expected from lower pricing of caustic soda and another sluggish year at Winchester, he said. Yet lower turnaround costs, further epoxy recovery, caustic contract pricing, higher EDC/chlorine pricing and lower hydrocarbon costs could boost growth, the analyst said. 

Olin has a strong balance sheet, with FCF of around $500 million likely to be spent on debt reduction and share repurchases, according to KeyBanc. 

Price Action

Olin shares were down 1.01 percent at $23.49 at the time of publication Monday. 

Related Links:

Benzinga's Top Upgrades, Downgrades For January 28, 2019

Mid-Day Market Update: Crude Oil Up Over 2%; Quanex Building Products Shares Plunge Following Q4 Results

Latest Ratings for OLN

Date Firm Action From To
Jan 2019 KeyBanc Initiates Coverage On Overweight
Dec 2018 Stifel Nicolaus Initiates Coverage On Buy
Nov 2018 Citigroup Maintains Buy Buy

View More Analyst Ratings for OLN
View the Latest Analyst Ratings

See more from Benzinga

© 2019 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.